In a significant development for respiratory health, a medical technology firm based in India has successfully completed its Series B funding round, raising an impressive $14.8 million. This amount exceeds the initial target of $12 million, showcasing strong investor confidence in the company’s innovative solutions for airway clearance and ventilation.
The funding round was spearheaded by the chairman of the board, who is also a managing partner at a prominent venture capital firm. This oversubscribed round attracted participation from various investors, both new and existing, highlighting the growing interest in advanced respiratory care technologies.
PRODUCT OVERVIEW
The company’s flagship product, an advanced airway clearance system, is designed to assist individuals in clearing mucus and enhancing airway function. This innovative device utilizes saline to thin mucus, employs air pulses and vibrations to facilitate mucus expulsion from the lungs, and maintains consistent pressure to ensure open airways. Notably, it minimizes the release of aerosol particles, making it suitable for both home and hospital use.
The newly acquired funds will be strategically allocated to boost the commercialization of this airway clearance system, expand sales efforts in the U.S. market, invest in clinical research, and enhance patient engagement through digital health initiatives.
According to the CEO of the company, this investment represents a crucial milestone in their mission to broaden access to their respiratory therapy platform, ultimately delivering transformative solutions to more patients in need.
INDUSTRY INSIGHTS
In 2024, the company received expanded regulatory clearance for its airway clearance system, allowing its use in acute care settings alongside ventilators. This expanded indication provides healthcare facilities with a valuable therapeutic option for patients experiencing atelectasis, retained secretions, or pneumonia.
The respiratory care market is witnessing the emergence of various players, including a Taiwanese company that recently gained regulatory approval in the U.S. for its AI-driven technology that measures respiratory rates without contact. This innovative solution utilizes a smartphone’s camera to monitor vital signs, including heart rate and oxygen saturation.
Additionally, a South Korean application designed for respiratory rehabilitation has been approved, offering an eight-week program aimed at improving the aerobic capacity of individuals with chronic respiratory conditions. This highlights the ongoing advancements in digital health solutions aimed at enhancing respiratory care.